Use of surgical gamma probe for the detection of lymph node metastases in differentiated thyroid cancer

被引:8
作者
Lippi, F
Capezzone, M
Miccoli, P
Traino, C
Di Martino, F
Angelini, F
Spinelli, C
Iacconi, P
Pinchera, A
Pacini, F
机构
[1] Univ Pisa, Dipartimento Endocrinol & Metab, I-56124 Pisa, Italy
[2] Univ Pisa, Dipartimento Chirurg, I-56124 Pisa, Italy
[3] Azienda Osped Pisana, Serv Fis Sanitaria, Pisa, Italy
关键词
differentiated thyroid cancer; radioiodine-treatment; surgical gamma probe; I-131; therapy; whole body scan;
D O I
10.1177/030089160008600433
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: patients with differentiated thyroid cancer (DTC) after total or near-total thyroidectomy require I-131 therapy. After surgery the persistence of lymph node metastases in our series of patients was frequent (30%). Such patients are preferentially treated with radioiodine and shifted to surgical reintervention when the nodal lesions persist after two I-131 treatments. Aim: Use of an intraoperative radioactive probe (C-TraK) to allow a more radical surgical approach in thyroid cancer patients submitted to surgery for lymph node metastases, Methods and results: After adequate withdrawal of L-thyroxine suppressive therapy six patients were given high I-131 doses followed by post-therapy WBS which demonstrated cervical activity in 5 patients and peri-jugular activity in 1. Surgery with the help of a gamma probe allowed to detect and remove all metastatic nodes. After excision all surgical specimens showed higher radioactive counts with respect to the background. The post-surgical scan showed the disappearance of all areas of I-131 uptake. Histology confirmed the presence of metastatic lesions from papillary thyroid cancer. Conclusions: We conclude that the use of a gamma probe can be successful in patients with metastatic neck lesions resistant to I-131 treatment, particularly in patients with nonpalpable lesions.
引用
收藏
页码:367 / 369
页数:3
相关论文
共 9 条
[1]   NATURAL-HISTORY, TREATMENT, AND COURSE OF PAPILLARY THYROID-CARCINOMA [J].
DEGROOT, LJ ;
KAPLAN, EL ;
MCCORMICK, M ;
STRAUS, FH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (02) :414-424
[2]   PAPILLARY THYROID-CARCINOMA [J].
HAY, ID .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1990, 19 (03) :545-576
[3]  
Maxon H., 1993, THYROID TODAY, V16, P1
[4]  
Öhrvall U, 1997, CANCER, V80, P2490
[5]   OUTCOME OF 309 PATIENTS WITH METASTATIC DIFFERENTIATED THYROID-CARCINOMA TREATED WITH RADIOIODINE [J].
PACINI, F ;
CETANI, F ;
MICCOLI, P ;
MANCUSI, F ;
CECCARELLI, C ;
LIPPI, F ;
MARTINO, E ;
PINCHERA, A .
WORLD JOURNAL OF SURGERY, 1994, 18 (04) :600-604
[6]  
PACINI F, 1987, J NUCL MED, V28, P1888
[7]   Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma [J].
Travagli, JP ;
Cailleux, AF ;
Ricard, M ;
Baudin, E ;
Caillou, B ;
Parmentier, C ;
Schlumberger, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (08) :2675-2680
[8]  
TUBIANA M, 1985, CANCER-AM CANCER SOC, V55, P794, DOI 10.1002/1097-0142(19850215)55:4<794::AID-CNCR2820550418>3.0.CO
[9]  
2-Z